Literature DB >> 2039469

Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function.

J Howl1, T Ismail, A J Strain, C J Kirk, D Anderson, M Wheatley.   

Abstract

The [Arg8]vasopressin (AVP) receptor expressed by human hepatocytes was characterized, and compared with the rat hepatic V1a vasopressin receptor subtype. In addition to determining the pharmacological profile of the human receptor, the cellular responses to AVP were measured in human and rat hepatocytes by assaying glycogen phosphorylase alpha activity and DNA synthesis. Marked differences were observed between human and rat hepatocytes regarding vasopressin receptors and the intracellular consequences of stimulation by AVP. Data presented in this paper demonstrate the following, (i) Vasopressin V1a receptors are present in low abundance on human hepatocytes. (ii) Species differences exist between human and rat V1a receptors with respect to the affinity of some selective antagonists. (iii) AVP-stimulated glycogen phosphorylase a activation in human hepatocytes was approx. 5% of that observed in rat cells. (iv) In contrast with rat hepatocytes, DNA synthesis in human cells in culture was not stimulated by AVP. It is concluded that vasopressin plays only a minor role in the regulation of human hepatic function. Furthermore, conclusions drawn from observations made with AVP and its analogues on rat hepatic function cannot be directly extrapolated to the human situation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039469      PMCID: PMC1151163          DOI: 10.1042/bj2760189

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  The activation of liver glycogen phosphorylase by vasopressin.

Authors:  S Keppens; H de Wulf
Journal:  FEBS Lett       Date:  1975-03-01       Impact factor: 4.124

2.  Hepatic action of vasopressin: lack of a role for adenosine-3',5'-cyclic monophosphate.

Authors:  C J Kirk; D A Hems
Journal:  FEBS Lett       Date:  1974-10-01       Impact factor: 4.124

3.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  The labelling of polyphosphoinositides with [32P]Pi and the accumulation of inositol phosphates in vasopressin-stimulated hepatocytes.

Authors:  S Palmer; P T Hawkins; R H Michell; C J Kirk
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

6.  Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Authors:  S Jard; R C Gaillard; G Guillon; J Marie; P Schoenenberg; A F Muller; M Manning; W H Sawyer
Journal:  Mol Pharmacol       Date:  1986-08       Impact factor: 4.436

7.  A selective binding site for 3H-NECA that is not an adenosine A2 receptor.

Authors:  M Keen; E Kelly; P Nobbs; J MacDermot
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

8.  Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver.

Authors:  D A Hems; P D Whitton
Journal:  Biochem J       Date:  1973-11       Impact factor: 3.857

9.  Stimulation, by vasopressin and other agonists, of inositol-lipid breakdown and inositol phosphate accumulation in WRK 1 cells.

Authors:  C J Kirk; G Guillon; M N Balestre; S Jard
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

10.  Gluconeogenesis in the perfused rat liver.

Authors:  R Hems; B D Ross; M N Berry; H A Krebs
Journal:  Biochem J       Date:  1966-11       Impact factor: 3.857

View more
  13 in total

1.  Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes.

Authors:  S R Hawtin; H C Howard; M Wheatley
Journal:  Biochem J       Date:  2001-03-01       Impact factor: 3.857

2.  Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

Authors:  J Tsukada; A Tahara; Y Tomura; T Kusayama; N Ishii; T Yatsu; W Uchida; N Taniguchi; A Tanaka
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 3.  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Authors:  Saptarshi Bhattacharya; Sanjay Kalra; Deep Dutta; Deepak Khandelwal; Rajiv Singla
Journal:  Eur Endocrinol       Date:  2019-10-18

4.  Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.

Authors:  J Howl; M Wheatley
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

Review 5.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

6.  Extrapituitary expression of the rat V1b vasopressin receptor gene.

Authors:  S J Lolait; A M O'Carroll; L C Mahan; C C Felder; D C Button; W S Young; E Mezey; M J Brownstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 7.  The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Benlei Li; Dong Fang; Cheng Qian; Hongliang Feng; Yanggan Wang
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

8.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Authors:  C Serradeil-Le Gal; J Wagnon; C Garcia; C Lacour; P Guiraudou; B Christophe; G Villanova; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 9.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

10.  Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium.

Authors:  A Jovanović; L Grbović; I Zikić; I Tulic
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.